Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ: CYTK )

44.40 +0.41 (+0.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Why CalAmp Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
NuScale Power, Stagwell And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Nasdaq Composite gaining around 50 points on Friday. Here are some big stocks recording gains in Friday's session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Where Cytokinetics Stands With Analysts
Via Benzinga
Where Cytokinetics Stands With Analysts
Via Benzinga
11 Analysts Have This to Say About Cytokinetics
Via Benzinga
What 20 Analyst Ratings Have To Say About Cytokinetics
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The 3 Best Mid-Cap Stocks to Buy Now: September 2023
With the best mid-cap stocks to buy, investors get the best of both worlds: an established business but with ample room to grow. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2023
Via Benzinga
18 Analysts Have This to Say About Cytokinetics
Via Benzinga
Cytokinetics: Q1 Earnings Insights
Via Benzinga
Analyst Ratings for Cytokinetics
Via Benzinga
Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies
Via Benzinga
Analyst Expectations for Cytokinetics's Future
Via Benzinga
Cytokinetics Plans To Discontinue Late-Stage ALS Trial Due To Futility
Cytokinetics Incorporated (NASDAQ: CYTK) announced that the Data Monitoring Committee (DMC) for COURAGE-ALS recently convened to conduct the second planned interim analysis of this Phase 3 clinical... 
Via Benzinga
Analyst Ratings for Cytokinetics
Via Benzinga
FDA Rejects Cytokinetics' Heart Failure Treatment Candidate
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle
Via Benzinga
Cytokinetics's Earnings: A Preview
Via Benzinga
Analyst Ratings for Cytokinetics
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap?
The company's biggest moneymakers are soon to lose patent protection. 
Via Investor's Business Daily
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2023
Via Benzinga
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
Tesla To $175? Here Are 10 Other Price Target Changes For Friday
Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS